Trial Profile
A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Shire; Shire Pharmaceutical Development
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Jun 2014 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry.
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.